Lakshminarayan R Ranganath Selected Research

nitisinone (Orfadin)

7/2022	Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients.
5/2022	Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria.
5/2022	Long-term low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression.
1/2022	Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.
1/2021	Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients.
1/2021	Characterising the arthroplasty in spondyloarthropathy in a large cohort of eighty-seven patients with alkaptonuria.
9/2020	Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.
1/2020	Nitisinone causes acquired tyrosinosis in alkaptonuria.
1/2020	Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
1/2020	Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lakshminarayan R Ranganath Research Topics

Disease

33	Alkaptonuria 07/2022 - 02/2011
13	Ochronosis 01/2021 - 12/2011
4	Inborn Genetic Diseases (Disease, Hereditary) 07/2022 - 02/2011
3	Osteoarthritis 01/2020 - 06/2015
2	Disease Progression 01/2022 - 01/2020
2	Rare Diseases (Rare Disease) 12/2021 - 01/2020
2	Spondylarthropathies 01/2021 - 01/2021
2	Tyrosinemias (Tyrosinemia) 01/2020 - 01/2019
2	Joint Diseases (Joint Disease) 01/2014 - 02/2011
1	Cataract (Cataracts) 07/2022
1	Cognitive Dysfunction 05/2022
1	Tyrosinosis 01/2020
1	Pain (Aches) 01/2019
1	Osteitis Deformans (Paget's Disease of Bone) 01/2019
1	Cartilage Diseases (Cartilage Disease) 06/2015
1	Bone Resorption 06/2015
1	Bone Diseases (Bone Disease) 06/2015
1	Metabolic Diseases (Metabolic Disease) 01/2014
1	Obesity 01/2008
1	Weight Gain 01/2008

Drug/Important Bio-Agent (IBA)

23	Homogentisic AcidIBA 07/2022 - 02/2011
18	nitisinone (Orfadin)FDA Link 07/2022 - 01/2014
12	Tyrosine (L-Tyrosine)FDA Link 07/2022 - 02/2011
9	Homogentisate 1,2-Dioxygenase (Homogentisate 1,2 Dioxygenase)IBA 07/2022 - 12/2011
8	EnzymesIBA 07/2022 - 02/2011
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2015
3	PolymersIBA 01/2014 - 12/2011
2	CollagenIBA 01/2021 - 01/2020
2	Phenylalanine (L-Phenylalanine)FDA Link 01/2020 - 01/2015
2	Diphosphonates (Bisphosphonates)IBA 01/2019 - 06/2015
2	Melanins (Melanin)IBA 05/2013 - 12/2011
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2022
1	Dietary ProteinsIBA 01/2020
1	Amino Acids FDA Link 01/2020
1	Zoledronic Acid (Zometa)FDA Link 01/2019
1	4-hydroxyphenylpyruvic acidIBA 01/2019
1	DioxygenasesIBA 01/2019
1	Cathepsin KIBA 06/2015
1	Complement System Proteins (Complement)IBA 01/2015
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 02/2011
1	Glucose (Dextrose)FDA LinkGeneric 01/2008
1	Biological ProductsIBA 01/2008
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2008

Therapy/Procedure

12	Therapeutics 07/2022 - 06/2015
1	Arthroplasty 01/2021
1	Diet Therapy (Therapy, Diet) 01/2020